<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105582</url>
  </required_header>
  <id_info>
    <org_study_id>TEBICA002</org_study_id>
    <nct_id>NCT04105582</nct_id>
  </id_info>
  <brief_title>Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells</brief_title>
  <official_title>Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Colombia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundaci√≥n Salud de los Andes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Colombia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project, the investigators propose the first clinical study in Colombia of
      vaccination of patients with triple-negative breast cancer (TNBC) using synthetic peptides
      that contain mutations of the tumor itself that will be presented to the immune system by
      autologous dendritic cells to assess immunogenicity and safety of this type of personalized
      vaccine. Achieving the specific objectives set out in this project will mean that the
      investigators can validate in Colombia the experimental design necessary to identify
      exclusive epitopes in the tumors of the participants in this study, and also that have been
      able to demonstrate the safety and immunogenicity of these vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects and Safety</measure>
    <time_frame>One year after innoculation</time_frame>
    <description>Number of participants with a treatment-related adverse event as associated with dendritic cells and neo-antigen inoculation assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neoantigen Immunogenicity</measure>
    <time_frame>6 months after last innoculation</time_frame>
    <description>Measurement of T cell response against tumor-specific neo-antigen assessed by interferon gamma release by ELISPOT or ELISA of in vitro culture of T cells and mutated peptide-pulsed dendritic cells, normalized against wild type peptide.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neo-antigen pulsed Dendritic cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neo-antigen pulsed Dendritic cell</intervention_name>
    <description>Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide</description>
    <arm_group_label>Neo-antigen pulsed Dendritic cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a patient who is prescribed as a treatment for her cancer initiating neo-adjuvant
             chemotherapy with Doxorubicin / cyclophosphamide (A / C) administered prior to cycles
             with Taxanes and followed by surgery to remove the tumor.

          -  Be between 18 and 75 years old.

          -  That the patient agrees to participate in the Clinical Study prior to the start of
             chemotherapy.

          -  Have free venous access.

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Heart disease.

          -  Diabetes

          -  Renal impairment

          -  Coagulation disorders

          -  Have been hospitalized in the last month

          -  Have another active tumor with the exception of skin tumors of the squamous-cell or
             basal-cell carcinoma.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A Parra-Lopez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Full Professor School of Medicine. Microbiology Department.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos A Parra-Lopez, MD PhD</last_name>
    <phone>5713165000</phone>
    <phone_ext>15039</phone_ext>
    <email>caparral@unal.edu.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Gonzalez</last_name>
    <phone>5713165000</phone>
    <phone_ext>15016</phone_ext>
    <email>rgonzalezc@unal.edu.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidad Nacional de Colombia</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>111321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A parra-Lopez, MD PhD</last_name>
      <phone>3023742804</phone>
      <email>caparral@unal.edu.co</email>
    </contact>
    <investigator>
      <last_name>Calos A Parra-Lopez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Bernal-Estevez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Nacional de Colombia</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>111321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A parra-Lopez, MD PhD</last_name>
      <phone>3023742804</phone>
      <email>caparral@unal.edu.co</email>
    </contact>
    <investigator>
      <last_name>Calos A Parra-Lopez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Bernal Estevez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dendritic cells</keyword>
  <keyword>Neo-antigen</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not going to share individual participant data (IPD)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

